Eli Lilly’s weight-loss pill didn’t work so well, and the stock is tumbling

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

Previous Article

There are few assets hated like coal — why this dirty fuel may have a future

Next Article

Bank of England committee was so divided there were two votes on interest rates

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

− 1 = 1
Powered by MathCaptcha

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨